PDA Biosimilars Conference
-
Lisa Carlson
P6: Control Strategy for Biosimilars (with Case Studies)
-
John Geigert, PhD
Breakfast Session: CMC Considerations for Global Registrations
-
Jose Gomes
(NEW) P4: Additional Practical Considerations for Analytical Similarity (Case Studies)
-
Laurie Graham, PhD
(NEW) P6: Control Strategy for Biosimilars (with Case Studies)
-
Maria-Teresa Gutierrez-Lugo, PhD
(NEW) P7: Product Specifications for Biosimilars
-
Alan Herman, PhD
P3: Demonstrating Analytical Similarity (with case studies)
-
Christopher Holloway, PhD
P1: Opening Plenary Session: Current Agency Expectations for Approval for Biosimilars
-
Christopher Holloway, PhD
P5: Post Marketing Change Management
-
Margaret Karow, PhD
P2: Establishing QTPP for Biosimilars (Case Studies)
-
Steven Kozlowski, MD
(NEW) P1: Opening Plenary Session: Current Agency Expectations for Approval for Biosimilars
-
Stephan Krause, PhD
(UPDATED) P8: Closing Plenary: Other Practical Considerations for Biosimilars (Case Studies)
-
Mark McCamish, MD, PhD
P5: Post Marketing Change Management
-
Emily Shacter, PhD
(UPDATED) P7: Product Specifications for Biosimilars
-
Marjorie Shapiro, PhD
P3: Demonstrating Analytical Similarity (with case studies)
-
Corinna Sonderegger, PhD
(UPDATED) P2: Establishing QTPP for Biosimilars (Case Studies)
-
Corinna Sonderegger, PhD
P8: Closing Plenary - Other Practical Considerations for Biosimilars (Case Studies)
-
Harry Yang, PhD
P4: Additional Practical Considerations for Analytical Similarity (Case Studies)